aptaTargets is a clinical-stage biotechnology company that specializes in the development of therapeutic applications utilizing aptamer technology. Their lead candidate, ApTOLL, is a neuroprotective drug designed to target inflammation during the acute phase of conditions such as acute ischemic stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis. ApTOLL is unique in its approach, as it is the only drug currently under development that aims to treat stroke by blocking TLR4 activation, thereby mitigating the inflammatory response that can lead to significant tissue damage.

The company has a robust pipeline of programs at various stages of development. Currently, ApTOLL is undergoing a Phase Ib/IIa trial to evaluate its safety and neuroprotective effects in patients with acute ischemic stroke, while also being tested in a Phase Ib trial for COVID-19 patients at risk of severe inflammatory responses. Additionally, preclinical studies are being conducted to assess ApTOLL's efficacy in treating intracerebral hemorrhage, myocardial infarction, and multiple sclerosis, focusing on its anti-inflammatory, cardioprotective, and neuroprotective properties across different experimental models.

Spain

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

Cardiovascular Diseases

Infectious Diseases

Nervous System Diseases

Pathological Conditions

aptaTargets

Acute ischemic stroke

aptaTargets Program 1

Small Molecule Pharmaceuticals

COVID-19

aptaTargets Program 2

Intracerebral Hemorrhage

aptaTargets Program 3

Acute myocardial infarction

aptaTargets Program 4

Multiple sclerosis

Europe - West

Peptide Therapies

RNA Therapies

Therapeutic

aptaTargets

Company Details